Medical device stalwart to steer Camstent expansion in the US
Camstent Ltd., a Cambridge company applying proprietary bacteria-phobic polymer coatings to medical devices, has appointed medical device doyen Mark Harwood as CEO to help steer expansion throughout the US.
Harwood is returning to the UK from Malaysia where he spent two and a half years undertaking consultancy and M & A projects with healthcare businesses in the region. This included transforming a family-run emergency services business into a mid-sized corporation.
In the UK, Harwood is best known for his time as CEO of PneumaCare, a Cambridge-based respiratory monitoring medical imaging company. There he developed a range of respiratory products, instigated global clinical studies, published numerous papers and significantly expanded the company’s distribution network and sales.
Harwood spent a number of years in the US in leading roles in medical device companies including president and CEO of Arjo Huntleigh, global vice-president of Baxter International Inc., and president of RF Technologies (North America & EMEA).
Camstent’s founder and CTO, Dave Hampton, said: “We are very fortunate to have Mark join us as CEO. His arrival comes at a critical time for Camstent and the board believes he will play a pivotal role in the company’s next stage of development.
“He has an outstanding track record of growing small medical device companies into global players as well as managing large teams where he oversees all aspects of a business including sales, marketing and manufacturing.
“He also has extensive regulatory and quality experience which will be key for us as we look to expand our sales into the US, a market where he has a considerable knowledge.”
Harwood said: “I am joining Camstent at a very exciting time for the business and I am looking forward to working in the UK once again.
“Camstent’s bacteria-phobic coatings have the potential to become real game-changers in the battle against infections caused by medical devices.”
Camstent’s mission is to address the problem of hospital-acquired infections that affect one in 25 patients (300,000 people in England and 1.7 million in the US). Thirty-eight per cent of these are the result of catheter associated urinary infections, increasing patient morbidity and length of hospital stays.
In the US, as many as 99,000 patients die from these infections every year; 37,000 in Europe and almost 10,000 in the UK.
After extensive development by Camstent, the bacteria-phobic polymers, which were first discovered at the University of Nottingham in 2012, have been formulated as a coating for catheters and other silicon/silastic medical devices.